Cornering HIV: Taking advantage of interactions between selective pressures

Medical Hypotheses

Volumn 69, Issue 2, 2007, Pages 422-431

  Avila Rios S ^a   Reyes Teran G ^a   Espinosa, E ^a  

^a INSTITUTO NACIONAL DE ENFERMEDADES RESPIRATORIAS   (Mexico)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; APOLIPOPROTEIN B MESSENGER RNA EDITING ENZYME CATALYTIC POLYPEPTIDE 3F; APOLIPOPROTEIN B MESSENGER RNA EDITING ENZYME CATALYTIC POLYPEPTIDE 3G; GAG PROTEIN; INTEGRASE; LENS EPITHELIUM DERIVED GROWTH FACTOR; NEF PROTEIN; NEUTRALIZING ANTIBODY; PROTEIN P75; PROTEOME; TUMOR SUSCEPTIBILITY GENE 101 PROTEIN; VIF PROTEIN; VIRUS PROTEIN;

ADAPTIVE IMMUNITY; ANTIBODY RESPONSE; ARTICLE; CYTOTOXIC T LYMPHOCYTE; DRUG TARGETING; EXPERIMENTAL TEST; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN IMMUNODEFICIENCY VIRUS; HYPOTHESIS; INFECTION CONTROL; NONHUMAN; PRIORITY JOURNAL; PROPHYLAXIS; SELECTIVE PRESSURE; VIRUS ATTENUATION; VIRUS GENOME; VIRUS INHIBITION; VIRUS MUTATION; VIRUS REPLICATION;

ADAPTATION, PHYSIOLOGICAL; ANTI-HIV AGENTS; HIV; HIV INFECTIONS; HUMANS; VIRUS REPLICATION;

HUMAN IMMUNODEFICIENCY VIRUS;

EID: 34249339797     PISSN: 03069877     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mehy.2006.12.012     Document Type: Article

References (81)

1. Hu D.J., Dondero T.J., Rayfield M.A., George J.R., Schochetman G., Jaffe H.W., et al. The emerging genetic diversity of HIV. The importance of global surveillance for diagnostics, research, and prevention. JAMA 275 (1996) 210-216
2. Rambaut A., Posada D., Crandall K.A., and Holmes E.C. The causes and consequences of HIV evolution. Nat Rev Genet 5 (2004) 52-61
3. Mansky L.M., and Temin H.M. Lower in vivo mutation rate of human immunodeficiency virus type 1 than that predicted from the fidelity of purified reverse transcriptase. J Virol 69 (1995) 5087-5094
4. Hemelaar J., Gouws E., Ghys P.D., and Osmanov S. Global and regional distribution of HIV-1 genetic subtypes and recombinants in 2004. AIDS 20 (2006) W13-W23
5. Goulder P.J., and Watkins D.I. HIV and SIV CTL escape: implications for vaccine design. Nat Rev Immunol 4 (2004) 630-640
6. Wensing A.M., and Boucher C.A. Worldwide transmission of drug-resistant HIV. AIDS Rev 5 (2003) 140-155
7. Moore C.B., John M., James I.R., Christiansen F.T., Witt C.S., and Mallal S.A. Evidence of HIV-1 adaptation to HLA-restricted immune responses at a population level. Science 296 (2002) 1439-1443
8. Altfeld M., and Allen T.M. Hitting HIV where it hurts: an alternative approach to HIV vaccine design. Trends Immunol 27 (2006) 504-510
9. Blankson J.N., Bailey J.R., and Siliciano R.F. Crosscurrents in HIV-1 evolution. Nat Immunol 7 (2006) 121-122
10. Borrow P., Lewicki H., Wei X., Horwitz M.S., Peffer N., Meyers H., et al. Antiviral pressure exerted by HIV-1-specific cytotoxic T lymphocytes (CTLs) during primary infection demonstrated by rapid selection of CTL escape virus. Nat Med 3 (1997) 205-211
11. Price D.A., Goulder P.J., Klenerman P., Sewell A.K., Easterbrook P.J., Troop M., et al. Positive selection of HIV-1 cytotoxic T lymphocyte escape variants during primary infection. Proc Natl Acad Sci USA 94 (1997) 1890-1895
12. Allen T.M., Altfeld M., Geer S.C., Kalife E.T., Moore C., O'Sullivan K.M., et al. Selective escape from CD8+ T-cell responses represents a major driving force of human immunodeficiency virus type 1 (HIV-1) sequence diversity and reveals constraints on HIV-1 evolution. J Virol 79 (2005) 13239-13249
13. Frahm N., Kiepiela P., Adams S., Linde C.H., Hewitt H.S., Sango K., et al. Control of human immunodeficiency virus replication by cytotoxic T lymphocytes targeting subdominant epitopes. Nat Immunol 7 (2006) 173-178
14. Leslie A.J., Pfafferott K.J., Chetty P., Draenert R., Addo M.M., Feeney M., et al. HIV evolution: CTL escape mutation and reversion after transmission. Nat Med 10 (2004) 282-289
15. Friedrich T.C., Dodds E.J., Yant L.J., Vojnov L., Rudersdorf R., Cullen C., et al. Reversion of CTL escape-variant immunodeficiency viruses in vivo. Nat Med 10 (2004) 275-281
16. Peyerl F.W., Barouch D.H., and Letvin N.L. Structural constraints on viral escape from HIV- and SIV-specific cytotoxic T-lymphocytes. Viral Immunol 17 (2004) 144-151
17. Edwards C.T., Pfafferott K.J., Goulder P.J., Phillips R.E., and Holmes E.C. Intrapatient escape in the A*0201-restricted epitope SLYNTVATL drives evolution of human immunodeficiency virus type 1 at the population level. J Virol 79 (2005) 9363-9366
18. Furutsuki T., Hosoya N., Kawana-Tachikawa A., Tomizawa M., Odawara T., Goto M., et al. Frequent transmission of cytotoxic-T-lymphocyte escape mutants of human immunodeficiency virus type 1 in the highly HLA-A24-positive Japanese population. J Virol 78 (2004) 8437-8445
19. Goulder P.J., Brander C., Tang Y., Tremblay C., Colbert R.A., Addo M.M., et al. Evolution and transmission of stable CTL escape mutations in HIV infection. Nature 412 (2001) 334-338
20. Piontkivska H., and Hughes A.L. Patterns of sequence evolution at epitopes for host antibodies and cytotoxic T-lymphocytes in human immunodeficiency virus type 1. Virus Res 116 (2006) 98-105
21. Leslie A., Kavanagh D., Honeyborne I., Pfafferott K., Edwards C., Pillay T., et al. Transmission and accumulation of CTL escape variants drive negative associations between HIV polymorphisms and HLA. J Exp Med 201 (2005) 891-902
22. Johnson V.A., Brun-Vezinet F., Clotet B., Kuritzkes D.R., Pillay D., Schapiro J.M., et al. Update of the drug resistance mutations in HIV-1: Fall 2006. Top HIV Med 14 (2006) 125-130
23. Cane P., Chrystie I., Dunn D., Evans B., Geretti A.M., Green H., et al. Time trends in primary resistance to HIV drugs in the United Kingdom: multicentre observational study. BMJ 331 (2005) 1368
24. Weinstock H., Respess R., Heneine W., Petropoulos C.J., Hellmann N.S., Luo C.C., et al. Prevalence of mutations associated with reduced antiretroviral drug susceptibility among human immunodeficiency virus type 1 seroconverters in the United States, 1993-1998. J Infect Dis 182 (2000) 330-333
25. Frahm N., Korber B.T., Adams C.M., Szinger J.J., Draenert R., Addo M.M., et al. Consistent cytotoxic-T-lymphocyte targeting of immunodominant regions in human immunodeficiency virus across multiple ethnicities. J Virol 78 (2004) 2187-2200
26. Karlsson A.C., Deeks S.G., Barbour J.D., Heiken B.D., Younger S.R., Hoh R., et al. Dual pressure from antiretroviral therapy and cell-mediated immune response on the human immunodeficiency virus type 1 protease gene. J Virol 77 (2003) 6743-6752
27. Mason R.D., Bowmer M.I., Howley C.M., Gallant M., Myers J.C., and Grant M.D. Antiretroviral drug resistance mutations sustain or enhance CTL recognition of common HIV-1 Pol epitopes. J Immunol 172 (2004) 7212-7219
28. John M., Moore C.B., James I.R., and Mallal S.A. Interactive selective pressures of HLA-restricted immune responses and antiretroviral drugs on HIV-1. Antivir Ther 10 (2005) 551-555
29. Mason R.D., and Grant M.D. A therapy-related point mutation changes the HLA restriction of an HIV-1 Pol epitope from A2 to B57 and enhances its recognition. AIDS 19 (2005) 981-984
30. Deeks S.G., Schweighardt B., Wrin T., Galovich J., Hoh R., Sinclair E., et al. Neutralizing antibody responses against autologous and heterologous viruses in acute versus chronic human immunodeficiency virus (HIV) infection: evidence for a constraint on the ability of HIV to completely evade neutralizing antibody responses. J Virol 80 (2006) 6155-6164
31. Emu B., Sinclair E., Favre D., Moretto W.J., Hsue P., Hoh R., et al. Phenotypic, functional, and kinetic parameters associated with apparent T-cell control of human immunodeficiency virus replication in individuals with and without antiretroviral treatment. J Virol 79 (2005) 14169-14178
32. Casazza J.P., Betts M.R., Hill B.J., Brenchley J.M., Price D.A., Douek D.C., et al. Immunologic pressure within class I-restricted cognate human immunodeficiency virus epitopes during highly active antiretroviral therapy. J Virol 79 (2005) 3653-3663
33. Iversen A.K., Stewart-Jones G., Learn G.H., Christie N., Sylvester-Hviid C., Armitage A.E., et al. Conflicting selective forces affect T cell receptor contacts in an immunodominant human immunodeficiency virus epitope. Nat Immunol 7 (2006) 179-189
34. Ali A., Ng H.L., Dagarag M.D., and Yang O.O. Evasion of cytotoxic T lymphocytes is a functional constraint maintaining HIV-1 Nef expression. Eur J Immunol 35 (2005) 3221-3228
35. Ali A., Pillai S., Ng H., Lubong R., Richman D.D., Jamieson B.D., et al. Broadly increased sensitivity to cytotoxic T lymphocytes resulting from Nef epitope escape mutations. J Immunol 171 (2003) 3999-4005
36. Peng B., and Robert-Guroff M. Deletion of N-terminal myristoylation site of HIV Nef abrogates both MHC-1 and CD4 down-regulation. Immunol Lett 78 (2001) 195-200
37. Swann S.A., Williams M., Story C.M., Bobbitt K.R., Fleis R., and Collins K.L. HIV-1 Nef blocks transport of MHC class I molecules to the cell surface via a PI 3-kinase-dependent pathway. Virology 282 (2001) 267-277
38. Yang O.O., Nguyen P.T., Kalams S.A., Dorfman T., Gottlinger H.G., Stewart S., et al. Nef-mediated resistance of human immunodeficiency virus type 1 to antiviral cytotoxic T lymphocytes. J Virol 76 (2002) 1626-1631
39. Swigut T., Alexander L., Morgan J., Lifson J., Mansfield K.G., Lang S., et al. Impact of Nef-mediated downregulation of major histocompatibility complex class I on immune response to simian immunodeficiency virus. J Virol 78 (2004) 13335-13344
40. Calugi G., Montella F., Favalli C., and Benedetto A. The Entire Genome of a nef-Deleted Strain of Human Immunodeficency Virus Type 1 recovered 20 years after Primary Infection: large pool of env-deleted proviruses. J Virol (2006)
41. Greenberg M.E., Iafrate A.J., and Skowronski J. The SH3 domain-binding surface and an acidic motif in HIV-1 Nef regulate trafficking of class I MHC complexes. Embo J 17 (1998) 2777-2789
42. Mangasarian A., Piguet V., Wang J.K., Chen Y.L., and Trono D. Nef-induced CD4 and major histocompatibility complex class I (MHC-I) down-regulation are governed by distinct determinants: N-terminal alpha helix and proline repeat of Nef selectively regulate MHC-I trafficking. J Virol 73 (1999) 1964-1973
43. Bradley C.M., and Craigie R. Seeing is believing: structure of the catalytic domain of HIV-1 integrase in complex with human LEDGF/p75. Proc Natl Acad Sci USA 102 (2005) 17543-17544
44. Ciuffi A., and Bushman F.D. Retroviral DNA integration: HIV and the role of LEDGF/p75. Trends Genet 22 (2006) 388-395
45. De Rijck J., Vandekerckhove L., Gijsbers R., Hombrouck A., Hendrix J., Vercammen J., et al. Over-expression of the LEDGF/p75 Integrase binding domain inhibits HIV replication. J Virol (2006)
46. Llano M., Saenz D.T., Meehan A., Wongthida P., Peretz M., Walker W.H., et al. An essential role for LEDGF/p75 in HIV integration. Science 314 (2006) 461-464
47. Vandekerckhove L., Christ F., Van Maele B., De Rijck J., Gijsbers R., Van den Haute C., et al. Transient and stable knockdown of the integrase cofactor LEDGF/p75 reveals its role in the replication cycle of human immunodeficiency virus. J Virol 80 (2006) 1886-1896
48. Maertens G.N., Cherepanov P., and Engelman A. Transcriptional co-activator p75 binds and tethers the Myc-interacting protein JPO2 to chromatin. J Cell Sci 119 (2006) 2563-2571
49. Turlure F., Maertens G., Rahman S., Cherepanov P., and Engelman A. A tripartite DNA-binding element, comprised of the nuclear localization signal and two AT-hook motifs, mediates the association of LEDGF/p75 with chromatin in vivo. Nucleic Acids Res 34 (2006) 1653-1675
50. Rahman S., Lu R., Vandegraaff N., Cherepanov P., and Engelman A. Structure-based mutagenesis of the integrase-LEDGF/p75 interface uncouples a strict correlation between in vitro protein binding and HIV-1 fitness. Virology (2006)
51. Cherepanov P., Ambrosio A.L., Rahman S., Ellenberger T., and Engelman A. Structural basis for the recognition between HIV-1 integrase and transcriptional coactivator p75. Proc Natl Acad Sci USA 102 (2005) 17308-17313
52. Cherepanov P., Sun Z.Y., Rahman S., Maertens G., Wagner G., and Engelman A. Solution structure of the HIV-1 integrase-binding domain in LEDGF/p75. Nat Struct Mol Biol 12 (2005) 526-532
53. Emiliani S., Mousnier A., Busschots K., Maroun M., Van Maele B., Tempe D., et al. Integrase mutants defective for interaction with LEDGF/p75 are impaired in chromosome tethering and HIV-1 replication. J Biol Chem 280 (2005) 25517-25523
54. Harris R.S., Bishop K.N., Sheehy A.M., Craig H.M., Petersen-Mahrt S.K., Watt I.N., et al. DNA deamination mediates innate immunity to retroviral infection. Cell 113 (2003) 803-809
55. Mangeat B., Turelli P., Caron G., Friedli M., Perrin L., and Trono D. Broad antiretroviral defence by human APOBEC3G through lethal editing of nascent reverse transcripts. Nature 424 (2003) 99-103
56. Zhang H., Yang B., Pomerantz R.J., Zhang C., Arunachalam S.C., and Gao L. The cytidine deaminase CEM15 induces hypermutation in newly synthesized HIV-1 DNA. Nature 424 (2003) 94-98
57. Pace C., Keller J., Nolan D., James I., Gaudieri S., Moore C., et al. Population level analysis of human immunodeficiency virus type 1 hypermutation and its relationship with APOBEC3G and vif genetic variation. J Virol 80 (2006) 9259-9269
58. Conticello S.G., Harris R.S., and Neuberger M.S. The Vif protein of HIV triggers degradation of the human antiretroviral DNA deaminase APOBEC3G. Curr Biol 13 (2003) 2009-2013
59. Marin M., Rose K.M., Kozak S.L., and Kabat D. HIV-1 Vif protein binds the editing enzyme APOBEC3G and induces its degradation. Nat Med 9 (2003) 1398-1403
60. Yu X., Yu Y., Liu B., Luo K., Kong W., Mao P., et al. Induction of APOBEC3G ubiquitination and degradation by an HIV-1 Vif-Cul5-SCF complex. Science 302 (2003) 1056-1060
61. Mehle A., Goncalves J., Santa-Marta M., McPike M., and Gabuzda D. Phosphorylation of a novel SOCS-box regulates assembly of the HIV-1 Vif-Cul5 complex that promotes APOBEC3G degradation. Genes Dev 18 (2004) 2861-2866
62. Mehle A., Thomas E.R., Rajendran K.S., and Gabuzda D. A zinc-binding region in Vif binds Cul5 and determines cullin selection. J Biol Chem 281 (2006) 17259-17265
63. Tian C., Yu X., Zhang W., Wang T., Xu R., and Yu X.F. Differential requirement for conserved tryptophans in human immunodeficiency virus type 1 Vif for the selective suppression of APOBEC3G and APOBEC3F. J Virol 80 (2006) 3112-3115
64. Yu Y., Xiao Z., Ehrlich E.S., Yu X., and Yu X.F. Selective assembly of HIV-1 Vif-Cul5-ElonginB-ElonginC E3 ubiquitin ligase complex through a novel SOCS box and upstream cysteines. Genes Dev 18 (2004) 2867-2872
65. Jeffrey Fessel W. A new approach to an AIDS vaccine: creating antibodies to HIV vif will enable apobec3G to turn HIV-infection into a benign problem. Med Hypotheses 64 (2005) 261-263
66. Yasuda J. HIV budding and Tsg101. Uirusu 55 (2005) 281-286
67. Barbaro G., Scozzafava A., Mastrolorenzo A., and Supuran C.T. Highly active antiretroviral therapy: current state of the art, new agents and their pharmacological interactions useful for improving therapeutic outcome. Curr Pharm Des 11 (2005) 1805-1843
68. Garrus J.E., von Schwedler U.K., Pornillos O.W., Morham S.G., Zavitz K.H., Wang H.E., et al. Tsg101 and the vacuolar protein sorting pathway are essential for HIV-1 budding. Cell 107 (2001) 55-65
69. von Schwedler U.K., Stuchell M., Muller B., Ward D.M., Chung H.Y., Morita E., et al. The protein network of HIV budding. Cell 114 (2003) 701-713
70. Holguin A., Alvarez A., and Soriano V. Variability in the P6gag domains of HIV-1 involved in viral budding. AIDS 20 (2006) 624-627
71. Richman D.D., Wrin T., Little S.J., and Petropoulos C.J. Rapid evolution of the neutralizing antibody response to HIV type 1 infection. Proc Natl Acad Sci USA 100 (2003) 4144-4149
72. Albert J., Abrahamsson B., Nagy K., Aurelius E., Gaines H., Nystrom G., et al. Rapid development of isolate-specific neutralizing antibodies after primary HIV-1 infection and consequent emergence of virus variants which resist neutralization by autologous sera. AIDS 4 (1990) 107-112
73. Burton D.R., Stanfield R.L., and Wilson I.A. Antibody vs. HIV in a clash of evolutionary titans. Proc Natl Acad Sci USA 102 (2005) 14943-14948
74. Frost S.D., Wrin T., Smith D.M., Kosakovsky Pond S.L., Liu Y., Paxinos E., et al. Neutralizing antibody responses drive the evolution of human immunodeficiency virus type 1 envelope during recent HIV infection. Proc Natl Acad Sci USA 102 (2005) 18514-18519
75. Reeves J.D., Lee F.H., Miamidian J.L., Jabara C.B., Juntilla M.M., and Doms R.W. Enfuvirtide resistance mutations: impact on human immunodeficiency virus envelope function, entry inhibitor sensitivity, and virus neutralization. J Virol 79 (2005) 4991-4999
76. Labrosse B., Morand-Joubert L., Goubard A., Rochas S., Labernardiere J.L., Pacanowski J., et al. Role of the envelope genetic context in the development of enfuvirtide resistance in human immunodeficiency virus type 1-infected patients. J Virol 80 (2006) 8807-8819
77. Lataillade M., and Kozal M.J. The hunt for HIV-1 integrase inhibitors. AIDS Patient Care STDS 20 (2006) 489-501
78. Brigo A., Lee K.W., Iurcu Mustata G., and Briggs J.M. Comparison of multiple molecular dynamics trajectories calculated for the drug-resistant HIV-1 integrase T66I/M154I catalytic domain. Biophys J 88 (2005) 3072-3082
79. Lee D.J., and Robinson Jr. W.E. Human immunodeficiency virus type 1 (HIV-1) integrase: resistance to diketo acid integrase inhibitors impairs HIV-1 replication and integration and confers cross-resistance to l-chicoric acid. J Virol 78 (2004) 5835-5847
80. Sakalian M., McMurtrey C.P., Deeg F.J., Maloy C.W., Li F., Wild C.T., et al. 3-O-(3′,3′-dimethysuccinyl) betulinic acid inhibits maturation of the human immunodeficiency virus type 1 Gag precursor assembled in vitro. J Virol 80 (2006) 5716-5722
81. Li F., Goila-Gaur R., Salzwedel K., Kilgore N.R., Reddick M., Matallana C., et al. PA-457: a potent HIV inhibitor that disrupts core condensation by targeting a late step in Gag processing. Proc Natl Acad Sci USA 100 (2003) 13555-13560